Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P39 versus Xolair in chronic spontaneous urticaria
2020-000952-36Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab biosimilar SYN008 and omalizumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Celltrion. Primary endpoint: Change from baseline in weekly itch severity score at Week 12. Started Jul 2020; status: completed.
02
Drugs
omalizumab biosimilar SYN008omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2020-000952-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000952-36.